Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

medpace holdings - MEDP

MEDP

Close Chg Chg %
312.36 -7.67 -2.46%

Closed Market

304.69

-7.67 (2.46%)

Volume: 602.60K

Last Updated:

Mar 31, 2025, 4:00 PM EDT

Trade Now

Company Overview: medpace holdings - MEDP

MEDP Key Data

Open

$308.45

 Day Range

289.01 - 308.45

52 Week Range

289.01 - 459.77

 Market Cap

$9.52B

Shares Outstanding

30.47M

 Public Float

24.67M

Beta

1.47

 Rev. Per Employee

N/A

P/E Ratio

24.73

 EPS

$13.06

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

394.71K

  

MEDP Performance

1 Week
 
 -3.66%
 
1 Month
 
 -4.57%
 
3 Months
 
 -5.98%
 
1 Year
 
 -22.71%
 
5 Years
 
 358.81%
 

MEDP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 13
Full Ratings ➔

About medpace holdings - MEDP

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

MEDP At a Glance

Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati, Ohio 45227
Phone 1-513-579-9911 Revenue 2.11B
Industry Miscellaneous Commercial Services Net Income 404.34M
Sector Commercial Services 2024 Sales Growth 11.836%
Fiscal Year-end 12 / 2025 Employees 5,900
View SEC Filings

MEDP Valuation

P/E Current 25.15
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 26.304
Price to Sales Ratio 5.043
Price to Book Ratio 12.299
Price to Cash Flow Ratio 17.47
Enterprise Value to EBITDA 21.247
Enterprise Value to Sales 4.797
Total Debt to Enterprise Value 0.015

MEDP Efficiency

Revenue/Employee 357,466.78
Income Per Employee 68,532.542
Receivables Turnover 7.115
Total Asset Turnover 1.123

MEDP Liquidity

Current Ratio 0.932
Quick Ratio 0.932
Cash Ratio 0.606

MEDP Profitability

Gross Margin 29.732
Operating Margin 21.188
Pretax Margin 22.566
Net Margin 19.172
Return on Assets 21.521
Return on Equity 58.41
Return on Total Capital 41.468
Return on Invested Capital 48.927

MEDP Capital Structure

Total Debt to Total Equity 18.112
Total Debt to Total Capital 15.335
Total Debt to Total Assets 7.117
Long-Term Debt to Equity 15.291
Long-Term Debt to Total Capital 12.946
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Medpace Holdings - MEDP

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.14B 1.46B 1.89B 2.11B
Sales Growth
+23.38% +27.80% +29.17% +11.84%
Cost of Goods Sold (COGS) incl D&A
835.34M 1.05B 1.39B 1.48B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
37.41M 40.36M 26.33M 29.25M
Depreciation
32.29M 37.00M 24.13M 27.81M
Amortization of Intangibles
5.11M 3.35M 2.20M 1.44M
COGS Growth
+25.29% +25.69% +32.17% +6.80%
Gross Income
307.04M 410.10M 498.18M 627.05M
Gross Income Growth
+18.46% +33.57% +21.48% +25.87%
Gross Profit Margin
+26.88% +28.09% +26.42% +29.73%
2021 2022 2023 2024 5-year trend
SG&A Expense
108.42M 131.40M 161.35M 180.18M
Research & Development
- - - -
-
Other SG&A
108.42M 131.40M 161.35M 180.18M
SGA Growth
+17.65% +21.19% +22.79% +11.67%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
198.62M 278.70M 336.82M 446.87M
Non Operating Income/Expense
3.34M 7.07M (655.00K) 29.05M
Non-Operating Interest Income
- - - 25.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 105.00K 2.90M 488.00K
Interest Expense Growth
- - +2,666.67% -83.20%
-
Gross Interest Expense
- 105.00K 2.90M 488.00K
Interest Capitalized
- - - -
-
Pretax Income
201.85M 282.86M 335.68M 475.92M
Pretax Income Growth
+19.77% +40.13% +18.67% +41.78%
Pretax Margin
+17.67% +19.37% +17.80% +22.57%
Income Tax
20.00M 37.49M 52.87M 71.54M
Income Tax - Current - Domestic
54.54M 57.15M 73.23M 92.28M
Income Tax - Current - Foreign
2.58M 3.33M 4.62M 5.88M
Income Tax - Deferred - Domestic
(36.30M) (23.00M) (25.99M) (25.54M)
Income Tax - Deferred - Foreign
(820.00K) 13.00K 1.01M (1.08M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
(458.00K) (157.00K) (191.00K) (44.00K)
Consolidated Net Income
181.39M 245.21M 282.62M 404.34M
Minority Interest Expense
- - - -
-
Net Income
181.39M 245.21M 282.62M 404.34M
Net Income Growth
+25.16% +35.18% +15.26% +43.07%
Net Margin Growth
+15.88% +16.80% +14.99% +19.17%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
181.39M 245.21M 282.62M 404.34M
Preferred Dividends
- - - -
-
Net Income Available to Common
181.39M 245.21M 282.62M 404.34M
EPS (Basic)
5.058 7.571 9.1992 13.0614
EPS (Basic) Growth
+24.37% +49.68% +21.51% +41.98%
Basic Shares Outstanding
35.86M 32.39M 30.72M 30.96M
EPS (Diluted)
4.8118 7.2826 8.876 12.6302
EPS (Diluted) Growth
+25.20% +51.35% +21.88% +42.30%
Diluted Shares Outstanding
37.70M 33.67M 31.84M 32.01M
EBITDA
236.02M 319.05M 363.15M 476.12M
EBITDA Growth
+17.72% +35.18% +13.82% +31.11%
EBITDA Margin
+20.66% +21.85% +19.26% +22.58%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 356.75
Number of Ratings 13 Current Quarters Estimate 3.049
FY Report Date 06 / 2025 Current Year's Estimate 12.306
Last Quarter’s Earnings 3.083 Median PE on CY Estimate N/A
Year Ago Earnings 12.63 Next Fiscal Year Estimate 13.70
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 9 9
Mean Estimate 3.05 3.03 12.31 13.70
High Estimates 3.11 3.13 12.60 14.31
Low Estimate 2.96 2.90 12.07 12.76
Coefficient of Variance 1.84 2.81 1.27 3.09

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 8 7 6
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Medpace Holdings - MEDP

Date Name Shares Transaction Value
Mar 11, 2025 August James Troendle CEO; Director 692,073 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $54.74 per share 37,884,076.02
Mar 11, 2025 Kevin M. Brady CFO & Treasurer 6,591 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Susan E. Burwig Exec. VP, Operations 11,017 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Stephen P. Ewald General Counsel & Corp. Secy. 6,591 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Jesse J. Geiger President 9,886 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 August James Troendle CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 August James Troendle CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 August James Troendle CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 August James Troendle CEO; Director 73,443 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 August James Troendle CEO; Director 1,011,102 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $107.93 per share 109,128,238.86
Mar 11, 2025 August James Troendle CEO; Director 926,332 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $56.61 per share 52,439,654.52
Mar 3, 2025 Stephen P. Ewald General Counsel & Corp. Secy. 13,343 Open market or private purchase of non-derivative security Non-derivative transaction at $326.11 per share 4,351,285.73
Feb 27, 2025 Brian T. Carley Director 30,035 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $42.62 per share 1,280,091.70
Feb 27, 2025 Brian T. Carley Director 26,032 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $345.59 per share 8,996,398.88
Feb 27, 2025 Brian T. Carley Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 Cornelius P. McCarthy Director 5,287 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 Cornelius P. McCarthy Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 Robert O. Kraft Director 662 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 Robert O. Kraft Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 4, 2024 Dani S. Zander Director 824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Medpace Holdings in the News